Homologous Recombination Deficiency (HRD) Testing in Ovarian Cancer
Update: 2022-11-11
Description
Isabelle Ray-Coquard, MD, PhD, explains how comprehensive genomic profiling (CGP) simultaneously provides HRD and BRCA status in ovarian cancer patients. She presents the case of a patient who benefited from CGP testing for these biomarkers and shares the recent findings of the PAOLA-1 trial.
Comments
In Channel